MedTrace Logo

Argus II Retinal Prosthesis System Dry AMD Feasibility Study Protocol

NCT02227498 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2020-03-18

No results posted yet for this study

Summary

The purpose of this study is to test the Argus II Retinal Prosthesis System in patients with severe age-related macular degeneration (AMD). The Argus II System has already been studied in completely blind patients with retinitis pigmentosa (RP). In RP patients, some cells of the retina are irrevocably damaged and the Argus II System has been found to restore some basic visual function. On these grounds, the device has received authorization for use on the European market (the CE certification) in 2011.

Conditions

  • Age Related Macular Degeneration

Interventions

DEVICE

Effect of Argus II on Functional Vision

To evaluate the safety and effectiveness of the Argus II Retinal Prosthesis in subjects with AMD.

Sponsors & Collaborators

  • Second Sight Medical Products

    lead INDUSTRY

Principal Investigators

  • Jessy Dorn, PhD · Second Sight Medical Products, Inc.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
25 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-06-30
Primary Completion
2019-09-30
Completion
2020-03-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02227498 on ClinicalTrials.gov